The JNKCF Information Site on Clinical Trials

Welcome to the Judy Nicholson Kidney Cancer Foundation Information site on Clinical Trials! On the webpage below, you will find videos on how you can find Clinical Trials, as well as the type of information you should know about them before you enroll. You will also find information on all active clinical trials involving renal cell carcinoma in the State of Florida. You should start by downloading and completing the Cancer Details Checklist below.

If you have any additional questions about Clinical Trials, please do not hesitate to reach out to us via email at: clinicaltrials@jnfkidneycancer.org.

Download PDF Tutorials here:
Cancer Details Checklist
How do I find a Clinical Trial for Kidney Cancer
Questions to Ask Your Doctor about Clinical Trials as an Option

 

Clinical Trials – Open Recruiting in Florida

  1. Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
    Principal Investigator: Mayer Fishman, M.D., Ph.D.
    ClinicalTrials.gov ID#: NCT02964078
    Phase: 2
    Location: Hem-Onc Associates of Treasure Coast
    Port Saint Lucie, Florida, United States, 34952
    Contact: Cortlin Croft
    Phone: 813-745-7559
    Email: cortlin.croft@moffitt.org

    Type of Trial: Advanced RCC – Prior Treatment
  2. Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
    Principal Investigator: Nikhil I Khushalani, MDH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    ClinicalTrials.gov ID#: NCT02718066

    Phase: 1B/2
    Location: Hem-Onc Associates of Treasure Coast
    Port Saint Lucie, Florida, United States, 34952
    Contact: Dmitri Kharkevitch, MD, PhD
    Phone: 858-798-8800
    Email: dkharkevitch@huyabio.com
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information: Experimental: HBI-8000 in combination with nivolumab
  3. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
    ClinicalTrials.gov ID#: NCT01806064
    Phase: 1 & 2
    Location: “University of Florida” – Gainesville, Florida, United States
    University of Miami – Miami, Florida, United States
    Moffitt Cancer Center – Tampa, Florida, United States”Status: Recruiting
    Email:  Clinicaltrials@traconpharma.com
    Type of Trial: Advanced RCC – Prior PD-1, PD-L1 Allowed
  4. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
    Principal Investigator: Winston W. Tan
    ClinicalTrials.gov ID#: NCT01767636
    Phase: 2
    Location: Mayo Clinic
    Jacksonville, Florida, United States, 32224-9980
    Status: Recruiting
    Contact: Clinical Trials Referral Office
    Phone: 855-776-0015
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information:
    Non-Clear RCC, Only one prior treatment allowed.
  5. A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
    Phase: 2
    ClinicalTrials.gov ID#: NCT02915783
    Location: H. Lee Moffitt Cancer Center
    Contact: Eisai Medical Services
    Phone: 1-888-274-2378
    Email: esi_medinfo@eisai.com
    Type of Trial: Advanced RCC – No Prior Treatment
  6. A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
    ClinicalTrials.gov ID#: NCT03024996
    Phase: 2
    Location: Univ of Miami, School of Med; Hem/Onc
    Miami, Florida, United States, 33136
    Moffitt Cancer Center
    Tampa, Florida, United States, 33612
    Contact: www.roche.com/about_roche/roche_worldwide.htm
    Phone: 888-662-6728 (U.S. and Canada)
    Email: global-roche-genentech-trials@gene.com
    Type of Trial: Adjuvant
    Related Information: Nephrectomy required
  7. A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
    ClinicalTrials.gov ID#: NCT02684006
    Phase: 3
    Location: Moffitt Cancer Center and Research Institute Tampa Florida, 33612
    Status: Recruiting
    Contact: Pfizer CT.gov Call Center
    Phone: 1-800-718-1021
    Type of Trial: Advanced RCC – No Prior Treatment
  8. Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
    Clinical Trials.gov ID: NCT01727336
    Phase: 2
    Location: H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida, United States

    Status: Recruiting
    Contact: Clinical Trials Manager 
    Email: dalanterceptclinicaltrials@acceleronpharma.com
    Type of Trial: Advanced RCC – No Prior Treatment
  9. Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
    ClinicalTrials.gov ID: NCT02667886
    Phase: 1 & 2
    Location: Jacksonville, Florida, United States
    Status: Recruiting
    Contact: Sarah Blanchette, PhD
    Email: patientinfo@x4pharma.com
    Type of Trial: Advanced RCC – Prior treatment with PD-1, PD-L1 Allowed
  10. A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
    ClinicalTrials.gov ID:
    NCT02982954
    Phase: 4
    Principal Investigator: Bristol-Myers Squibb
    Location: Florida Cancer Specialists S.
    Fort Myers, Florida, United States, 33901
    Orlando Health, Orlando, Florida, United States, 32806
    Status: Recruiting
    Email: Clinical.Trials@bms.com
    Type of Trial: Advanced RCC – No Prior Treatment
  11. Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT02811861
    Phase: 3
    Location: University of Miami
    Miami, Florida, United States
    Status: Recruiting
    Contact: Eisai Medical Information
    Phone: 1-888-274-2378
    Email: esi_medinfo@eisai.com
    Type of Trial: Advanced RCC – No Prior Treatment
  12. An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT03029780
    Phase: 2 
    Location: Cancer Specialists of North FL
    Jacksonville, Florida, United States, 32256
    Status: Recruiting
    Contact: Bijoy Telivala, Site 0010 
    Phone: 1-888-274-2378
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information: No prior checkpoint inhibitors
  13. Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
    ClinicalTrials.gov ID:
    NCT02853344
    Phase: 2
    Principal Investigator: Merck Sharp & Dohme Corp.
    Location: Call for Information (Investigational Site 8007)
    Miami, Florida, United States,33143
    Status: Recruiting 
    Phone: 1-888-577-8839
    Type of Trial: Advanced RCC – No prior treatment
  14. Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    ClinicalTrials.gov ID:
    NCT02761057
    Phase: 2
    Principal Investigator: Michael A. Schwartz
    Location: Mount Sinai Medical Center
    Miami Beach, Florida, United States, 33140
    Status: Recruiting
    Contact: Michael A. Schwartz
    Phone: 305-674-2625 
    Email: info@msccop.com
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information: Papillary RCC
  15. Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
    ClinicalTrials.gov ID:
    NCT01164228
    Phase: 2
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: Mayo Clinic – Jacksonville
    Jacksonville, Florida, United States, 32224
    Status: Recruiting 
    Phone: 507-538-7623 
    Type of Trial: Advanced RCC – No Prior Treatment
    Related Information: Advanced Renal Cell Carcinoma with Sarcomatoid features
  16. A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT02293980
    Phase: 1
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136, 305-243-1287
    Status: Recruiting
    Contact: Richard Kelley
    Phone: 972-629-4081  
    Email: clinicalstudies@pelotontx.com
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
  17. A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
    ClinicalTrials.gov ID:
    NCT02627963
    Phase: 3
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136
    Status: Recruiting
    Contact: Darlene Wilson, dwilson@aveooncology.com
    Michael Needle, MD mneedle@aveooncology.com
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
  18. A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors
    ClinicalTrials.gov ID:
    NCT02576665
    Phase: 1
    Principal Investigator: Jaime R Merchan, MDUniversity of Miami
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136
    Status: Recruiting
    Contact: Jamie Merchan, MD 305-243-1287 jmerchan2@med.miami.edu
    Tamara Leon Aliz (305) 243-0865 txl351@med.miami.edu
    Type of Trial: Neoadjuvant
    Related Information: Should enroll prior to nephrectomy
  19. A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
    ClinicalTrials.gov ID:
    NCT02599324
    Phase: 1 & 2
    Principal Investigator: Mehdi M Moezi, MD
    Location: Cancer Specialists, LLC, Department of Clinical Research Recruiting
    Jacksonville, Florida, United States, 32256
    Status: Recruiting
    Contact: Jenni Bachhofer 904-363-7462 ext 1179 Jenni.Bachhofer@CSNF.us
    Judy Bulacan 904-264-6201 Judy.Bulacan@CSNF.us
    Type of Trial: Advanced RCC – Prior Treatment
  20. Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
    ClinicalTrials.gov ID:
    NCT02071862
    Phase: 1
    Principal Investigator: Manish R Patel, MD
    Location: Florida Cancer Specialists
    Sarasota, Florida, United States, 34232
    Status: Recruiting
    Phone: 941-377-9993
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
  21. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
    ClinicalTrials.gov ID:
     NCT02568267
    Phase: 2
    Principal Investigator:  Christine Chung, MD
    Location: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Tampa, Florida, United States, 33612
    Status: Recruiting
    Contact: Ignyta Inc.
    Phone: 1-844-782-7875
    Email: STARTRKtrials@ignyta.com
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
  22. Safety Study of MGA271 in Refractory Cancer
    ClinicalTrials.gov ID:
    NCT01391143
    Phase: 1
    Principal Investigator:  Christine Chung, MD
    Location: Moffitt Cancer Center Recruiting
    Tampa, Florida, United States, 33612
    Contact: Allison Richards, MS  
    Phone: 813-745-8352
    Email: allison.richards@moffitt.org
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Histologically or cytologically confirmed renal cell carcinoma that overexpresses B7-H3.
  23. Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
    ClinicalTrials.gov ID: NCT02315066
    Phase: 1
    Location: H. Lee Moffitt Cancer Center and Research Institute, Inc. Tampa, FL, United States, 33612
    Contact: Pfizer CT.gov Call Center
    Phone: 1-800-718-1021
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Solid Tumor with limited RCC Access
  24. Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
    ClinicalTrials.gov ID: NCT02646748
    Phase: 1
    Location: Port St. Lucie, FL, United States
    Contact: Incyte Corporation Call Center
    Phone: 1-855-463-3463
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Solid Tumor with limited RCC Access
  25. A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
    ClinicalTrials.gov ID: NCT02301117
    Phase: 1
    Principal Investigator: Robert Winkler, MD | 609-750-5300
    Location: Gainesville, FL, United States, 32610
    Contact: Robert Winkler, MD
    Phone: 1-855-598-8259
    Email: rwinkler@taihooncology.com
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Solid tumor for patients with renal impairment
  26. A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)
    ClinicalTrials.gov ID: NCT02178722
    Phase: 1 & 2
    Principal Investigator: Robert Winkler, MD | 609-750-5300
    Location: Miami, FL, United States
    Contact: Incyte Call Center
    Phone: 1-855-463-3463
    Type of Trial: Advanced RCC – Prior Treatment
  27. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    ClinicalTrials.gov ID: NCT02601950
    Phase: 2
    Principal Investigator: Steven Attia, MD
    Location: Mayo Clinic – Jacksonville, FL United States, 32224
    Contact: Rebecca Souliere
    Email: souliere.rebecca@mayo.edu
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Rhabdoid and Renal Medullary Kidney Cancer
  28. NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
    ClinicalTrials.gov ID: NCT02465060
    Phase: 2
    Principal Investigator: Alan H. Bryce
    Location: Mayo Clinic – Jacksonville, FL United States, 32224
    Contact: Alan H. Bryce | 855.776.0015
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Solid Tumor With Limited RCC Access
  29. A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
    ClinicalTrials.gov ID: NCT02335918
    Phase: 1 & 2
    Principal Investigator: Jose Lutzky, MD | jose.lutzky@msmc.com
    Location: Mount Sinai Medical Center Recruiting
    Miami Beach, Florida, United States, 33140

    Contact: Jose Lutzky, MD | jose.lutzky@msmc.com
    Type of Trial: Advanced RCC – Prior Treatment
  30. Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
    ClinicalTrials.gov ID: NCT02526017
    Phase: 1
    Principal Investigator: Heloisa Soares, MD, PhD
    Location: H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida, United States, 33612

    Contact: Medical Lead FPA008003@fiveprime.com
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information: Solid Tumor With Limited RCC Access
  31. Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
    ClinicalTrials.gov ID: NCT02298959
    Phase: 1
    Principal Investigator: Mayer N. Fishman
    Location: H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida, United States, 33612

    Contact: Mayer N. Fishman | 800.456.7121 | canceranswers@moffitt.org 
    Type of Trial: Advanced RCC – Prior Treatment
  32. Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
    ClinicalTrials.gov ID: NCT01631552
    Phase: 1 & 2
    Principal Investigator: Rebecca Moroose, MD
    Location: MD Anderson Cancer Center Orlando (UF Health Cancer Center) Orlando, FL
    Contact: Georgina Hollenbach, RN | Georgina.Hollenbach@orlandohealth.com 
    Type of Trial: Advanced RCC – Prior Treatment
    Related Information: Solid Tumor With Limited RCC Access
  33. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    ClinicalTrials.gov ID: NCT02867592
    Phase: 2
    Principal Investigator: Fouad M. Hajjar
    Location: Florida Hospital Orlando Recruiting | Orlando, FL, United States, 32803
    Contact: Fouad M. Hajjar | 407.303.2090 | fh.cancer.research@flhosp.org 
    Type of Trial: Advanced RCC – Prior Treatment with PD-1, PD-L1 Allowed
    Related Information: Pediatric, Kidney Cancer including Wilms